Our Prostate service assists prostate cancer diagnosis by integrating MRI delineation with real-time ultrasound during biopsies. The process starts with an MRI scan to map the prostate and identify suspicious lesions, especially for men with elevated PSA levels or abnormalities detected in a Digital Rectal Exam (DRE). AI is used to outline the prostate and lesions, which are then refined by technologists and reviewed by radiologists.

The resulting dataset, including lesion information and the PI-RADS score, guides transrectal biopsies with real-time ultrasound fusion, allowing precise targeting of MR-identified lesions. Post-biopsy, findings inform cancer management decisions, with the Gleason score determining the aggressiveness of cancer and subsequent treatments like surgery, radiation, hormone therapy, chemotherapy, or immunotherapy. The 3DQ Lab also provides 3D prints post-resection to guide prostate cutting for research.